Tablets India Ltd (TIL), a part of Rs 650 crore Jhaver group is restructuring its pharma division, with the introduction of its three new speciality pharma divisions namely, gastrology, gynaecology and surgeons. It is planning to invest close to Rs 20 crore for restructuring its pharma division. The expansion is expected to complete by the end of April 2008.

TIL, a leading manufacture of various pharmaceutical formulations and pioneers in amino acids therapy. The therapeutic range includes amino acid, orals and parenterals, biotherapeutics, respiratory medicine, anti ulcerants, nutritional supplements, hepatoprotectives, antioxidants, calcium supplements and herbo-nutraceuticals; a novel anti antipyretic, a unique G l lavage formulation, and a third generation Cephalosporin Injectable. The company is also diversifying into sports nutrition ,aquaculture and poultry feeds.

Speaking to Pharmabiz, S S Roy, vice president, marketing, said, "We are in the process of setting up three speciality division in our existing manufacturing facility. We are investing close to Rs 20 crore and it is expected to be commissioned by the end of April 2008. With the manpower strength of 150, we are planning to add 50 more peoples in our pharma division. Currently, our growth rate is 20 per cent and for the next two years we are expecting to grow at around 30-35 per cent".

The TIL Pharma division markets all its branded formulations in the domestic market through a well-trained field force of around 500 personnel. It has initiated and completed many clinical trials, through its clinical research arm, Jhaver research foundation, on its range of unique formulations, to bring to the medical profession the best in the field of contemporary medicine. The company has its own R&D set-up, which is recognized by the Ministry of science and technology.

Through its R&D efforts TIL has brought out many formulations like Astymin Forte, Astymin-M Forte, Astyfer-Z, Neutrosec, Fevastin Plus, Peglec, Glutazene, Calflavone, Bifilac and BioRS.

The company has a license agreement with the Japanese multinational Ajinomoto Pharma co, a subsidiary of the world leaders in the manufacture of Amino Acids, Ajinomoto co. Inc. Besides, the company has an agreement with F Hoffmann-La Roche Ltd Switzerland for manufacturing and marketing life saving drugs in anaesthesiology and gastroenterology. Its collaboration with Kotobuki Pharmaceutical co, Ltd. Japan has introduced a novel anti-gastric and direct ulcer-healing agent.